<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04240366</url>
  </required_header>
  <id_info>
    <org_study_id>19-323</org_study_id>
    <nct_id>NCT04240366</nct_id>
  </id_info>
  <brief_title>Additional Left Atrial Appendage Isolation During Balloon Ablation for Persistent or Long-standing Persistent Atrial Fibrillation</brief_title>
  <acronym>LALA-LAND-AF</acronym>
  <official_title>Additional Left Atrial Appendage Isolation During Balloon Ablation for Persistent or Long-standing Persistent Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Luebeck</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>IHF GmbH - Institut für Herzinfarktforschung</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Luebeck</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Additional left atrial appendage isolation during balloon ablation for persistent or
      long-standing persistent atrial ﬁbrillation can reduce atrial ﬁbrillation reoccurrence within
      3-12 months compared to balloon-based pulmonary vein isolation only.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 17, 2019</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time until any documented episode of ATa</measure>
    <time_frame>3 - 12 months</time_frame>
    <description>Time until any documented episode of atrial tachyarrhythmia (ATa: atrial fibrillation or atrial tachycardia) lasting longer than 30 seconds within 3-12 months after index ablation without antiarrhythmic therapy</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">310</enrollment>
  <condition>Persistent or Long-standing Persistent Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Balloon-based ablation of atrial fibrillation by pulmonary vein isolation alone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Balloon-based ablation of atrial fibrillation by pulmonary vein and left atrial appendage isolation</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Control intervention</intervention_name>
    <description>patients treated with balloon-based ablation of AF by PVI</description>
    <arm_group_label>Group 1</arm_group_label>
    <other_name>Balloon-based ablation of atrial fibrillation by pulmonary vein isolation alone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Experimental intervention</intervention_name>
    <description>patients treated with balloon-based ablation of AF by PVI</description>
    <arm_group_label>Group 2</arm_group_label>
    <other_name>Experimental: Group 2 Balloon-based ablation of atrial fibrillation by pulmonary vein and left atrial appendage isolation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Persistent or long-standing persistent AF (i.e. continuous AF that was/is sustained &gt;7
             days or &gt;12 months, respectively)

          2. Age ≥18 and ≤80 years

          3. Indication for AF ablation as per current guidelines

          4. Indication for LAA closure as per current guidelines

        Exclusion Criteria:

          1. Missing informed consent

          2. LAA diameter &gt;25mm 10mm distant from circumflex artery assessed by TEE

          3. Paroxysmal atrial ﬁbrillation

          4. Long-standing persistent atrial ﬁbrillation with a continuous AF duration of &gt;4 years

          5. Previous pulmonary vein isolation or MAZE surgery

          6. Previous led atrial appendage closure or surgical excision

          7. Left atrial diameter &gt;60 mm at baseline

          8. Left atrial thrombus at baseline
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Roland Tilz, Prof.</last_name>
    <email>roland.tilz@uksh.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Roza Meyer-Saraei, PhD</last_name>
    <phone>004945150044542</phone>
    <email>roza.meyer-saraei@uksh.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical clinic II-UKSH Luebeck, Schleswig-Holstein Germany</name>
      <address>
        <city>Lübeck</city>
        <state>Schleswig-Holstein</state>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roland Tilz, Prof. Dr. med.</last_name>
      <email>roland.tilz@uksh.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>December 18, 2019</study_first_submitted>
  <study_first_submitted_qc>January 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 27, 2020</study_first_posted>
  <last_update_submitted>January 23, 2020</last_update_submitted>
  <last_update_submitted_qc>January 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Luebeck</investigator_affiliation>
    <investigator_full_name>Prof. Roland Richard Tilz</investigator_full_name>
    <investigator_title>Head of Electrophysiology Department</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

